ArticleActa neurologica Belgica2026
Beyond relapse control: motor and cognitive subclinical progression in RRMS -a real-world longitudinal study of ocrelizumab and interferon beta.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system, with therapeutic goals focused on preventing disability progression and cognitive decline. This prospective, two-year study aimed to analyse the clinical and neuroradiological efficacy, disability progression, cognitive function, and safety profile in people with relapsing-remitting MS (RRMS) treated with ocrelizumab and IFN-beta 1a and 1b.
methodsThe study included 140 people with RRMS, evenly distributed into two treatment groups and followed over 24 months. Clinical parameters, test results and validated scales for assessing disease progression, cognitive function, as well as the safety profile were analyzed.
resultsA higher percentage of people with RRMS treated with ocrelizumab achieved no evidence of disease activity (NEDA-3; 74.3% vs. 57.1%; p = 0.033) and no evidence of progression or active disease (NEPAD; 71.4% vs. 51.4%; p = 0.025), with both outcomes showing a significant association with ocrelizumab therapy in binary logistic regression (NEDA-3: OR = 3.566; 95% CI: 1.251-10.169; p = 0.017; NEPAD: OR = 3.675; 95% CI: 1.365-9.893; p = 0.010). Motor function was more stable in ocrelizumab-treated patients, with fewer clinically meaningful deteriorations in walking speed compared with interferon beta (IFN-ß). Although both groups showed a gradual decline in 25FWT and 9HPT, progression was slower and occurred later with ocrelizumab. Cognitive performance remained stable with ocrelizumab, whereas IFN-ß was associated with SDMT decline over time and a significant reduction in MoCA scores (p = 0.002). Progression independent of relapse activity (PIRA) was observed in 13.6%, progression independent of both relapse and MRI activity (PIRMA) in 10.4%, with no significant differences between treatment groups. Significant SDMT decline was noted in 16 patients (11.7%). Among them, 7 (43.8%) had concomitant acute disease activity, while 9 (56.2%) exhibited cognitive PIRMA, mostly independent of EDSS worsening.
conclusionThe study results indicate the efficacy of ocrelizumab in achieving NEDA-3 and NEPAD, preserving cognitive and motor functions, with a favorable safety profile for both treatments. The results underscore the importance of longitudinal ambulatory and routine cognitive monitoring for detecting subclinical progression.
Indexed as
Identifiers
41975172What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.